Risk for breast cancer
| Analysis time | Antibody | Subtype | Person-years | No. observed | No. expected | SIR (95% CI) | P value |
| Overall risk | All | Limited | 26 624 | 42 | 57.6 | 0.73 (0.53 to 0.99) | 0.039 |
| Diffuse | 11 062 | 28 | 20.3 | 1.38 (0.91 to 1.99) | 0.123 | ||
| Cenp | Limited | 11 857 | 18 | 29.9 | 0.60 (0.36 to 0.95) | 0.027 | |
| Diffuse | 754 | 3 | 1.6 | 1.84 (0.38 to 5.39) | 0.45 | ||
| Topo | Limited | 4035 | 8 | 8.2 | 0.97 (0.42 to 1.92) | 0.99 | |
| Diffuse | 3134 | 5 | 5.3 | 0.95 (0.31 to 2.21) | 0.99 | ||
| Pol III | Limited | 962 | 1 | 1.9 | 0.52 (0.01 to 2.91) | 0.86 | |
| Diffuse | 2509 | 16 | 5.2 | 3.06 (1.75 to 4.98) | <0.001* | ||
| CTP-negative | Limited | 4065 | 12 | 7.2 | 1.66 (0.86 to 2.89) | 0.130 | |
| Diffuse | 1709 | 1 | 3 | 0.33 (0.01 to 1.83) | 0.39 | ||
| ±3 years | All | Limited | 7935 | 15 | 12.8 | 1.17 (0.66 to 1.94) | 0.60 |
| Diffuse | 5210 | 17 | 8.3 | 2.06 (1.20 to 3.29) | 0.010 | ||
| Cenp | Limited | 3003 | 4 | 5.4 | 0.75 (0.20 to 1.91) | 0.76 | |
| Diffuse | 212 | 0 | 0.4 | 0.00 (0.00 to 9.33) | 0.99 | ||
| Topo | Limited | 1353 | 1 | 2.1 | 0.48 (0.01 to 2.69) | 0.78 | |
| Diffuse | 1393 | 3 | 2 | 1.51 (0.31 to 4.41) | 0.64 | ||
| Pol III | Limited | 305 | 0 | 0.6 | 0.00 (0.00 to 6.66) | 0.99 | |
| Diffuse | 1209 | 12 | 2.3 | 5.14 (2.66 to 8.98) | <0.001* | ||
| CTP-negative | Limited | 1335 | 8 | 1.8 | 4.44 (1.92 to 8.74) | 0.001* | |
| Diffuse | 808 | 1 | 1.1 | 0.87 (0.02 to 4.86) | 0.99 |
↵*Statistically significant P value after adjustment for multiple (10) comparisons per analysis.
cenp, centromere; CTP, centromere, topoisomerase-1 and RNA polymerase III; pol, polymerase; topo, topoisomerase-1.